225 related articles for article (PubMed ID: 32993539)
1. A case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a case report.
Horikoshi K; Sakai N; Yamamoto N; Ogura H; Sato K; Miyagawa T; Kitajima S; Toyama T; Hara A; Iwata Y; Shimizu M; Furuichi K; Wada T
BMC Nephrol; 2020 Sep; 21(1):416. PubMed ID: 32993539
[TBL] [Abstract][Full Text] [Related]
2. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
3. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system.
Tanaka Y; Ohira T
Curr Opin Pharmacol; 2018 Jun; 40():110-119. PubMed ID: 29702364
[TBL] [Abstract][Full Text] [Related]
5. Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters.
Abe I; Ochi K; Takashi Y; Yamao Y; Ohishi H; Fujii H; Minezaki M; Sugimoto K; Kudo T; Abe M; Ohnishi Y; Mukoubara S; Kobayashi K
Medicine (Baltimore); 2019 Nov; 98(47):e18067. PubMed ID: 31764838
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
7. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
8. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
Park SY; Kim J; Chung HY
Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
[TBL] [Abstract][Full Text] [Related]
9. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
10. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
11. A case of denosumab-associated membranous nephropathy in a patient with rheumatoid arthritis.
Kimoto M; Fukunaga N; Yamaguchi N; Maruo M; Aoki K; Fukuda A; Nakata T; Hisano S; Shibata H
CEN Case Rep; 2020 Feb; 9(1):1-5. PubMed ID: 31544222
[TBL] [Abstract][Full Text] [Related]
12. Minimal change disease following the Moderna COVID-19 vaccine: first case report.
Thappy S; Thalappil SR; Abbarh S; Al-Mashdali A; Akhtar M; Alkadi MM
BMC Nephrol; 2021 Nov; 22(1):376. PubMed ID: 34763669
[TBL] [Abstract][Full Text] [Related]
13. Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis.
Lasco A; Morabito N; Basile G; Atteritano M; Gaudio A; Giorgianni GM; Morini E; Faraci B; Bellone F; Catalano A
Calcif Tissue Int; 2016 Feb; 98(2):123-8. PubMed ID: 26498169
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis.
Sutjandra L; Rodriguez RD; Doshi S; Ma M; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
Clin Pharmacokinet; 2011 Dec; 50(12):793-807. PubMed ID: 22087866
[TBL] [Abstract][Full Text] [Related]
15. RANKL as a target for the treatment of osteoporosis.
Matsumoto T; Endo I
J Bone Miner Metab; 2021 Jan; 39(1):91-105. PubMed ID: 33057808
[TBL] [Abstract][Full Text] [Related]
16. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.
Stokes MB; Markowitz GS; Lin J; Valeri AM; D'Agati VD
Kidney Int; 2004 May; 65(5):1690-702. PubMed ID: 15086908
[TBL] [Abstract][Full Text] [Related]
17. Complete Remission of Minimal Change Disease Following an Improvement of Lung Mycobacterium avium Infection.
Yamashiro A; Uchida T; Ito S; Oshima N; Oda T; Kumagai H
Intern Med; 2016; 55(18):2669-72. PubMed ID: 27629965
[TBL] [Abstract][Full Text] [Related]
18. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
Voskaridou E; Ntanasis-Stathopoulos I; Papaefstathiou A; Christoulas D; Dimopoulou M; Repa K; Papatheodorou A; Peppa M; Terpos E
Blood Adv; 2018 Nov; 2(21):2837-2847. PubMed ID: 30381400
[TBL] [Abstract][Full Text] [Related]
19. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
20. Severe hepatocytotoxicity linked to denosumab.
Malnick S; Maor Y; Melzer E; Ziv-Sokolowskaia NN; Neuman MG
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(1 Suppl):78-85. PubMed ID: 28379592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
